Abeona Therapeutics gets PDUFA date for its epidermolysis bullosa treatment
JHVEPhoto/iStock Editorial by way of Getty Photographs Abeona Therapeutics (NASDAQ:ABEO) introduced that the FDA has accepted for assessment Abeona’s resubmission of its Biologics License Utility for prademagene zamikeracel, its investigational autologous cell-based gene remedy, as a possible new therapy for recessive dystrophic epidermolysis bullosa. The FDA has assigned a Prescription Drug Person Price Act goal … Read more